139 related articles for article (PubMed ID: 9374903)
1. Funding of drug treatment of multiple sclerosis should not be delayed.
Paty DW
BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903
[No Abstract] [Full Text] [Related]
2. Rebif offers another option for treating multiple sclerosis.
Ryan M
J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
[No Abstract] [Full Text] [Related]
3. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
4. Beta interferon and multiple sclerosis: why the fuss?
Mumford CJ
QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
[No Abstract] [Full Text] [Related]
5. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
Bryant J; Clegg A; Milne R
BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
[No Abstract] [Full Text] [Related]
6. Bad decision NICE.
Ellis SJ
Lancet; 2002 Feb; 359(9304):447. PubMed ID: 11844551
[No Abstract] [Full Text] [Related]
7. A cost-utility analysis of interferon beta for multiple sclerosis.
Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
[No Abstract] [Full Text] [Related]
8. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
9. Shortcomings in pharmacy benefit forecasting--interferon beta products.
Rich SJ; Meyer C
J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
[No Abstract] [Full Text] [Related]
10. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Detournay B
Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
[No Abstract] [Full Text] [Related]
11. [Interferon-beta in multiple sclerosis--who is going to be treated?].
Aarli JA
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
[No Abstract] [Full Text] [Related]
12. Interferon beta in multiple sclerosis.
Richards RG
BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
[No Abstract] [Full Text] [Related]
13. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
McNaughton H; Kayes N; McPherson K
N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
[TBL] [Abstract][Full Text] [Related]
14. Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.
Thomas S
Nurs Stand; 2000 Jul 19-25; 14(44):20. PubMed ID: 11975272
[No Abstract] [Full Text] [Related]
15. Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?
Chaudhuri A; Behan PO
BMJ; 2003 May; 326(7400):1213. PubMed ID: 12775634
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.
Nuijten MJ; Hutton J
Value Health; 2002; 5(1):44-54. PubMed ID: 11873383
[TBL] [Abstract][Full Text] [Related]
17. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
Napier JC; Francis R; Wright G
BMJ; 2003 May; 326(7400):1212. PubMed ID: 12775633
[No Abstract] [Full Text] [Related]
18. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg A; Bryant J; Milne R
Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
[No Abstract] [Full Text] [Related]
19. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
Kappos L
Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
[No Abstract] [Full Text] [Related]
20. [Betaferon and therapy of multiple sclerosis--present and future].
Hohlfeld R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():1. PubMed ID: 11603109
[No Abstract] [Full Text] [Related]
[Next] [New Search]